{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:16:54Z","timestamp":1764494214355},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducted to investigate the survival benefit and the target characteristics of the anti-angiogenic agent in the EGFR L858R patients in our center, comparing those treated with or without anti-angiogenic therapy (cohort A and cohort B). At the median follow-up time of 31.0\u00a0months vs 32.7\u00a0months (cohort A vs. B) respectively, Cohort A (n\u2009=\u200958) had a significantly prolonged median OS compared to Cohort B (n\u2009=\u2009101) (60.0\u00a0months vs.37.0\u00a0months, HR 0.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.016). Anti-angiogenic therapy significantly prolonged the OS in patients with liver metastases (NA vs.26.0\u00a0months, HR 0.17, <jats:italic>p<\/jats:italic>\u2009=\u20090.023) comparing to patients without liver metastases (60.0\u00a0months vs.37.0\u00a0months, HR 0.63, p\u2009=\u20090.129). For brain metastatic patients, anti-angiogenic treatment tended to improve median OS with (65.0\u00a0months vs.35.0\u00a0months, HR 0.29, <jats:italic>p<\/jats:italic>\u2009=\u20090.068) or without brain radiotherapy (73.0\u00a0months vs.29.0\u00a0months, HR 0.24, <jats:italic>p<\/jats:italic>\u2009=\u20090.171). The grade 3 or more adverse events were manageable and consistent with previous studies. Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never received an anti-angiogenic agent. Patients with liver metastases might benefit more from anti-angiogenic therapy than those without.<\/jats:p>","DOI":"10.1038\/s41598-022-18889-z","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T19:03:06Z","timestamp":1661540586000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study"],"prefix":"10.1038","volume":"12","author":[{"given":"Liangkun","family":"You","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinnan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danchen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"18889_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"18889_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"18889_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clinthera.2019.12.006","volume":"42","author":"XY Li","year":"2020","unstructured":"Li, X. Y., Lin, J. Z. & Yu, S. H. Front-line therapy in advanced non-small cell lung cancer with sensitive epidermal growth factor receptor mutations: A network meta-analysis. Clin. Ther. 42, 338-350.e334 (2020).","journal-title":"Clin. Ther."},{"key":"18889_CR4","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu, W. H., Yang, J. C., Mok, T. S. & Loong, H. H. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 29, i3\u2013i9 (2018).","journal-title":"Ann. Oncol."},{"key":"18889_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"18889_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735\u2013742 (2011).","journal-title":"Lancet Oncol."},{"key":"18889_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17, 577\u2013589 (2016).","journal-title":"Lancet Oncol."},{"key":"18889_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","volume":"154","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer 154, 176\u2013185 (2021).","journal-title":"Lung Cancer"},{"key":"18889_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"18889_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"18889_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","volume":"72","author":"M Sheng","year":"2016","unstructured":"Sheng, M. et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: A meta-analysis. Eur. J. Clin. Pharmacol. 72, 1\u201311 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"18889_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang, J. C. et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16, 141\u2013151 (2015).","journal-title":"Lancet Oncol."},{"key":"18889_CR13","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","volume":"377","author":"RS Herbst","year":"2011","unstructured":"Herbst, R. S. et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 377, 1846\u20131854 (2011).","journal-title":"Lancet"},{"key":"18889_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto, T. et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15, 1236\u20131244 (2014).","journal-title":"Lancet Oncol."},{"key":"18889_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito, H. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 20, 625\u2013635 (2019).","journal-title":"Lancet Oncol."},{"key":"18889_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","volume":"151","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto, N. et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer 151, 20\u201324 (2021).","journal-title":"Lung Cancer"},{"key":"18889_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669 (2019).","journal-title":"Lancet Oncol."},{"key":"18889_CR18","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3751803","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. https:\/\/doi.org\/10.2139\/ssrn.3751803 (2021).","journal-title":"Cancer Cell"},{"key":"18889_CR19","doi-asserted-by":"publisher","first-page":"e183486","DOI":"10.1001\/jamaoncol.2018.3486","volume":"4","author":"C Gridelli","year":"2018","unstructured":"Gridelli, C. et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: The AvaALL randomized clinical trial. JAMA Oncol. 4, e183486 (2018).","journal-title":"JAMA Oncol."},{"key":"18889_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665\u2013673 (2014).","journal-title":"Lancet"},{"key":"18889_CR21","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","volume":"33","author":"CK Lee","year":"2015","unstructured":"Lee, C. K. et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J. Clin. Oncol. 33, 1958\u20131965 (2015).","journal-title":"J. Clin. Oncol."},{"key":"18889_CR22","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1007\/s00432-020-03311-w","volume":"146","author":"T Landre","year":"2020","unstructured":"Landre, T. et al. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J. Cancer Res. Clin. Oncol. 146, 3333\u20133339 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"18889_CR23","first-page":"473","volume":"32","author":"L Sun","year":"2015","unstructured":"Sun, L., Ma, J. T., Zhang, S. L., Zou, H. W. & Han, C. B. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Med. Oncol. 32, 473 (2015).","journal-title":"Med. Oncol."},{"key":"18889_CR24","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/j.cllc.2020.08.005","volume":"22","author":"Z Deng","year":"2021","unstructured":"Deng, Z., Qin, Y., Liu, Y., Zhang, Y. & Lu, Y. Role of antiangiogenic agents combined with EGFR tyrosine kinase inhibitors in treatment-naive lung cancer: A meta-analysis. Clin. Lung Cancer 22, e70\u2013e83 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"18889_CR25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/ijc.33677","volume":"149","author":"X Yu","year":"2021","unstructured":"Yu, X., Sheng, J., Pan, G. & Fan, Y. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Int. J. Cancer 149, 1121\u20131128 (2021).","journal-title":"Int. J. Cancer"},{"key":"18889_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12967-015-0622-x","volume":"13","author":"E Casta\u00f1\u00f3n","year":"2015","unstructured":"Casta\u00f1\u00f3n, E. et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. J. Transl. Med. 13, 257 (2015).","journal-title":"J. Transl. Med."},{"key":"18889_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/CCO.0000000000000591","volume":"32","author":"AR Cantelmo","year":"2020","unstructured":"Cantelmo, A. R. et al. Angiogenesis inhibition in non-small cell lung cancer: A critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. Curr. Opin. Oncol. 32, 44\u201353 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"18889_CR28","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana, T. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 3290 (2018).","journal-title":"J. Clin. Oncol."},{"key":"18889_CR29","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1200\/JCO.2007.12.1178","volume":"26","author":"A Kumar","year":"2008","unstructured":"Kumar, A., Petri, E. T., Halmos, B. & Boggon, T. J. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J. Clin. Oncol. 26, 1742\u20131751 (2008).","journal-title":"J. Clin. Oncol."},{"key":"18889_CR30","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00432-020-03296-6","volume":"146","author":"WQ Li","year":"2020","unstructured":"Li, W. Q. & Cui, J. W. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: Distinct mechanisms, different efficacies to treatments. J. Cancer Res. Clin. Oncol. 146, 2329\u20132338 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"18889_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2217\/fon.15.15","volume":"11","author":"N Reguart","year":"2015","unstructured":"Reguart, N. & Remon, J. Common EGFR-mutated subgroups (Del19\/L858R) in advanced non-small-cell lung cancer: Chasing better outcomes with tyrosine kinase inhibitors. Future Oncol. 11, 1245\u20131257 (2015).","journal-title":"Future Oncol."},{"key":"18889_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","volume":"25","author":"M Offin","year":"2019","unstructured":"Offin, M. et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer Res. 25, 1063\u20131069 (2019).","journal-title":"Clin. Cancer Res."},{"key":"18889_CR33","doi-asserted-by":"publisher","first-page":"13574","DOI":"10.1038\/srep13574","volume":"5","author":"MF Tsai","year":"2015","unstructured":"Tsai, M. F. et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci. Rep. 5, 13574 (2015).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18889-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18889-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18889-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T19:04:24Z","timestamp":1661540664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18889-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18889-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14624"}}